Weili Medical 2025 Annual Results Forecast
Securities code: 603309 Securities abbreviation: Weili Medical Announcement number: 2026-003 Guangzhou Weili Medical Equipment Co., Ltd.
2025 Annual Results Forecast
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Specific applicable situations for performance forecasts: Profitability is achieved, and net profit drops by more than 50% compared with the same period last year.
Guangzhou Weili Medical Equipment Co., Ltd. (hereinafter referred to as the "Company") is expected to achieve a net profit attributable to the owners of the parent company of RMB 75 million to RMB 95 million in 2025, which will be a decrease of RMB 144.39 million to RMB 124.39 million compared with the same period last year, a year-on-year decrease of 66% to 57%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be RMB 6,500 in 2025. Ten thousand yuan to 85 million yuan, a decrease of 145.02 million yuan to 125.02 million yuan compared with the same period last year, a year-on-year decrease of 69% to 60%.
1. Performance forecast for this period
(1) Performance forecast period
From January 1, 2025 to December 31, 2025.
(2) Performance forecast
According to preliminary calculations by the financial department, the net profit attributable to the owners of the parent company is expected to be 75 million to 95 million yuan in 2025. Compared with the same period last year, it will decrease by 144.39 million yuan to 124.39 million yuan, a year-on-year decrease of 66% to 57%.
It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2025 will be 65 million to 85 million yuan, which will decrease from 145.02 million yuan to 125.02 million yuan compared with the same period last year, a year-on-year decrease of 69% to 60%.
(3) The above performance forecast data are only preliminary accounting data and have not been audited by a certified public accountant.
2. Operating results for the same period last year
(1) Total profit: 263.0435 million yuan. Net profit attributable to owners of the parent company: 219.393 million yuan. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses: 210.0247 million yuan.
(2) Earnings per share: 0.75 yuan.
3. Main reasons for the pre-reduction of performance in this period
During the reporting period, the company's wholly-owned subsidiary Jiangxi Langhe Medical Devices Co., Ltd. (hereinafter referred to as "Langhe Medical") suffered a sharp decline in operating performance due to the slowdown in product market demand growth and fierce industry competition. The company acquired 100% equity of Langhe Medical in 2018, forming goodwill of RMB 269.367 million. Based on the current operating conditions of Langhe Medical and its analysis and forecast of its future operating conditions, the company's management initially judged that the goodwill formed by the acquisition of the company has shown signs of impairment. In order to reflect the company's financial status and asset value more objectively and fairly, in accordance with relevant accounting policies such as "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and the principle of prudence, the company is expected to accrue a goodwill impairment of RMB 147 million in 2025. The final amount of impairment will be determined after evaluation and audit by the evaluation agency and auditing agency hired by the company.
4. Risk warning
This performance estimate is a preliminary calculation based on the company's financial department's own professional judgment and has not yet been audited by an annual audit accounting firm. The amount of goodwill impairment provisions accrued by the company in 2025 is subject to the final audit and evaluation results. The final financial data may be different from the forecast data.
The company has pre-communicated with the annual audit accounting firm regarding the performance forecast. As of now, there are no major uncertain factors that affect the accuracy of the performance forecast.
5. Other explanations
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be based on the company's officially disclosed audited 2025 annual report. Investors are advised to pay attention to investment risks.
The company will maintain communication with the annual audit accountant during the preparation of subsequent annual reports. If there are major changes that may affect the accuracy of the performance forecast during the audit process, the company will promptly fulfill its information disclosure obligations.
Announcement is hereby made.
Board of Directors of Guangzhou Weili Medical Devices Co., Ltd.
January 8, 2026